No implying clinical significance from nonclinical/animal/in-vitro data alone

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

Favorable nonclinical (animal/in-vitro) data may not be presented in a way suggesting clinical significance that has not actually been demonstrated.

Check

Identify any animal/in-vitro data cited; confirm the ad does not imply clinical relevance beyond what has been clinically demonstrated.

Escalate when

Whether the presentation implies unproven clinical significance is a matter of interpretation.

Where this comes from

21 CFR 202.1(e)(6)(vii). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…references to literature or studies that misrepresent the effectiveness of a drug by failure to disclose that claimed results may be due to concomitant therapy, or by failure to disclose the credible information available concerning the extent to which claimed results may be due to placebo effect (information concerning placebo effect is not required unless the advertisement promotes the drug for use by man). (vii) Contains favorable data or conclusions from nonclinical studies of a drug, such as in laboratory animals or in vitro, in a way that suggests they have clinical significance when in fact no such clinical significance has been demonstrated. (viii) Uses a statement by a recognized authority that is apparently favorable about a drug but fails to refer to concurrent or more recent unfavorable data or statements from the same authority on the same subject or subjects. (ix) Uses a quote or paraphrase out of context to convey a false or misleading idea. (x) Uses literature, quotations, or references that purport to support an advertising claim but in fact…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is the complete, verbatim text of (e)(6)(vii) as it stands in the body of the regulation, and (e)(6) states these are ways an ad IS false, lacking in fair balance, or otherwise misleading — a binding prohibition, so the rule statement follows from it.
- Not overstated: the rule retains both halves of the source's condition — the data must be presented 'in a way that suggests they have clinical significance' AND clinical significance must not in fact have been demonstrated. It does not state a blanket ban on citing nonclinical data, which would have been broader than the source.
- Atomic: one checkable requirement about the manner of presenting nonclinical data.
- determinism 'judgment' is right: whether a presentation 'suggests' clinical significance is an impression question.
- authority 'binding' is correct; severity 'blocker' is defensible as an (e)(6) violation triggers section 502(n) misbranding; locator 21 CFR 202.1(e)(6)(vii) matches; applies_when 'promotional' is justified.
- Checked against the Effective Date Note: a 1979 revision of (e)(6)(vii) (which would have added the anti-infective in vitro disclaimer language) was stayed indefinitely and is reproduced only 'for the convenience of the user.' The rule correctly relies on the operative body text rather than the stayed version, so no change is needed.